@article{JTD31221,
author = {Claude Van Campenhout and Bárbara Meléndez and Myriam Remmelink and Isabelle Salmon and Nicky D’Haene},
title = {Blood tumor mutational burden: are we ready for clinical implementation?},
journal = {Journal of Thoracic Disease},
volume = {11},
number = {Suppl 15},
year = {2019},
keywords = {},
abstract = {Immunotherapy by using antibodies against the immune checkpoint inhibitor (ICI) PD-1 demonstrated objective durable responses in approximately 20% of patients with advanced non-small-cell lung cancer (NSCLC), melanoma, or renal-cell cancer (1).},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/31221}
}